Treatment of congestive heart failure: Experience with fosinopril

American Journal of Hypertension

Volumn 10, Issue 10 II SUPPL., 1997, Pages

  Blumenthal, Mel ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Congestive heart failure; Fosinopril

Indexed keywords

BENAZEPRILAT; CILAZAPRILAT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FOSINOPRIL; FOSINOPRILAT; LISINOPRIL; PERINDOPRILAT; QUINAPRILAT; RAMIPRILAT;

ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DRUG EFFICACY; DRUG EXCRETION; DRUG RESEARCH; HUMAN; PRIORITY JOURNAL; VERTIGO;

EID: 0030827394     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(97)00336-1     Document Type: Article

References (50)

1. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
2. McKee PA, Castell WP, McNamara PM, et al. The natural history of congestive heart failure the Framingham Heart Study . N Engl J Med. 285:1971;1441-1446.
3. Effect of enalapril on mortality in severe congestive heart failure Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med. 316:1987;1429-1435.
4. Gillum RF. Epidemiology of heart failure in the United States. Am Heart J. 126:1993;1042-1047.
5. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurements of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 105:1986;173-178.
6. Cooper RS, Simmons BE, Castaner A, et al. Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol. 65:1990;441-445.
7. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 115:1990;345-452.
8. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New Eng J Med. 322:1990;1561-1566.
9. Cody RJ, Ljungman S, Covit AB, et al. Regulation of glomerular filtration rate in chronic congestive heart failure patients. Kidney Int. 34:1988;361-367.
10. Parmley WW. Pathophysiology and current therapy of congestive heart failure. J Am Coll Cardiol. 13:1989;771-785.
11. Kleber FX, Wensel R. Current guidelines for the treatment of congestive heart failure. Drugs. 51:1996;889-898.
12. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336:1997;525-533.
13. Cohn JN. Vasodilator therapy for heart failure the influence of impedance on left ventricular performance . Circulation. 48:1973;5-8.
14. Cohn J, Franciosa J. Vasodilator therapy of cardiac failure. N Engl J Med. 297:1977;254-258.
15. Pfeffer MA. Angiotensin-converting enzyme inhibition in congestive heart failure benefit and perspective . Am Heart J. 126:1993;789-793.
16. Cohn JN, Archibald DG, Ziesche S, et al. Effects of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med. 314:1986;1547-1552.
17. Gavras H, Faxon DP, Berkoben J, et al. Angiotensin-converting enzyme inhibition in patients with congestive heart failure. Circulation. 58:1978;770-776.
18. Dzau VJ, Colucci WS, Williams GHQ, et al. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med. 302:1980;1373-1379.
19. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
20. Fonarow GC, Chelimsky-Fallick C, Stevenson LW, et al. Effect of direct vasodilatation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality severe congestive heart failure the Hy-C trial . J Am Coll Cardiol. 316:1992;1429-1435.
21. Francis GS. Pharmacologic treatment of congestive heart failure with standard drugs. Curr Opin Cardiol. 8:1993;404-410.
22. Braunwald E. ACE inhibitors a cornerstone of the treatment of heart failure . N Engl J Med. 325:1991;351-353.
23. Zanchetti A. Introduction in integrated care concepts with angiotensin-converting enzyme inhibition intervention for life . Am J Hypertens. 7(suppl):1994;67S-68S.
24. Seravalle G, Cattaneo BM, Giannattasio C, et al. RAA system and cardiovascular control in normal subjects, hypertensives and patients with congestive heart failure. J Hum Hypertens. (suppl 2):1993;S13-S18.
25. Pfeffer MA, Braunwald E, Moye L, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction - results of the Survival and Ventricular Enlargement Trial. New Engl J Med. 327:1992;669-677.
26. Guthrie R. Fosinopril an overview . Am J Cardiol. 72:1993;22H-24H.
27. Duchin KL, Waclowski AP, Tu JI, et al. Pharmacokinetics, safety and pharmacologic effects of fosinopril sodium, an angiotensin converting enzyme inhibitor in healthy subjects. J Clin Pharmacol. 31:1991;58-64.
28. Singhvi SM, Duchin KL, Morrison RA, et al. Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol. 25:1988;9-15.
29. Hui KK, Duchin KL, Kripalani KJ, et al. Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharm Ther. 49:1991;457-467.
30. Sica DA, Gehr TWB, Duchin KL. The pharmacology and pharmacokinetics of fosinopril. Contemp Pharmacother. 4:1993;1-15.
31. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol. 70:1992;479-487.
32. Shammas FV, Dickstein K. Clinical pharmacokinetics in heart failure An updated review . Clin Pharmacokinet. 15:1988;94-113.
33. O'Grady O, Mangold B, Yee K-F, Liao W: Fosinoprilat and enalaprilat pharmacokinetics in patients with congestive heart failure and renal insufficiency (abst). Third International Congress on Congestive Heart Failure, Geneva, Switzerland, May 1995.
34. Mangold B, O'Grady O, Yee K-F, Liao W: Fosinoprilat and lisinopril pharmacokinetics in patients with congestive heart failure and renal insufficiency (abst). Third International Congress on Heart Failure, Geneva, Switzerland, May 1995.
35. Sica DA, Cutler RE, Parmer RJ, Ford NF. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Clin Pharmacokinet. 20:1991;420-427.
36. Sica DA: Fosinopril: differential pharmacokinetics of a new class of ACE inhibitors, in Weber M (ed): Fosinopril: A New Generation of ACE Inhibitors Round Series No. 24. Royal Society of Medicine Services, London, 1990.
37. Fruncillo RJ, Rocci ML, Vlasses PH, et al. Disposition of enalapril and enalaprilat in renal insufficiency. Kid Intern. 31(suppl 20):1987;S117-S122.
38. Van Schaik BAM, Geyskes GG, Vanderwoun PA, et al. Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function. Eur J Clin Pharmacol. 34:1988;61-65.
39. Braunwald E. Heart failure pathophysiology and treatment . Am Heart J. 102:1981;486-490.
40. Szlachcic J, Massie BM, Kramer BL, et al. Correlates and prognostic implication of exercise capacity in chronic congestive heart failure. Am J Cardiol. 55:1985;1037-1042.
41. Cohn JN, Archibald DG, Francis GS, et al. Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate . Circulation. 75(suppl IV):1987;IV-49-IV-54.
42. Erhardt L, MacLean A, Ilgenfritz J, et al. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Eur Heart J. 16:1995;1892-1899.
43. Brown EJ, Chew PH, MacLean A, et al. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Am J Cardiol. 75:1995;596-600.
44. Deedwania PC. Clinical profile of fosinopril, a novel phosphinic acid ACE inhibitor, for the treatment of heart failure. Heart Failure. 11:1995;125-136.
45. Zusman RM. Angiotensin-converting enzyme inhibitors: more different than alike? Focus on cardiac performance . Am J Cardiol. 72:1993;25H-36H.
46. Stoller JK, Mehta A, Vidt D. Catopril-induced cough. Chest. 93:1988;659-661.
47. Goldszer RC, Lilly LS, Solomon HS. Prevention of cough during angiotensin converting enzyme inhibition therapy. Am J Med. 85:1988;887.
48. Gibson GR. Enalapril-induced cough. Arch Intern Med. 149:1989;2701-2703.
49. Germino FW, Lastra J, Pool P, et al. Evaluation of the cough profile of fosinopril in hypertensive patients with ACE inhibitor-associated cough - a pilot study. Curr Therapeut Res. 54:1993;469-475.
50. David D, Jallad N, Germino FW, et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE inhibitor-associated cough. Am J Therapeutics. 2:1995;806-813.